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Chronic myeloid leukemiaProtease-activated receptor 1 (PAR-1) is a G-protein-coupled receptor that is overexpressed in solid tumors,
being associated with several pro-tumoral responses including primary growth, invasion, metastasis and
angiogenesis. Expression of PAR-1 in human leukemic cell lines is reported but the status of its expression in
human leukemic patients is currently unknown. In this study we evaluated the expression pattern of PAR-1 in
patients with the four main types of leukemia – chronic lymphocytic leukemia subtype B (B-CLL), acute
lymphoblastic leukemia subtype B (B-ALL), acute myeloid leukemia (AML) and chronic myeloid leukemia
(CML). Flow cytometry analyses show that lymphocytes from B-CLL patients express this receptor at similar
levels to healthy individuals. On the other hand, it was observed a signiﬁcant increase in PAR-1 expression in
B-ALL lymphocytes as compared to B-CLL and healthy donors. Flow cytometric and real-time PCR
demonstrated a signiﬁcant increase in PAR-1 expression in granulocytes from CML patients in blast phase
(CML-BP) but not in chronic phase (CML-CP) as compared to healthy donors. Finally, a signiﬁcant increase in
PAR-1 expression has been also observed in blasts from AML (subtypes M4 and M5) patients, as compared to
monocytes or granulocytes from healthy donors. We conclude that PAR-1 might play an important biological
role in aggressive leukemias and might offer additional strategies for the development of new therapies.dica/CCS/UFRJ, Avenida Carlos
o, Rio de Janeiro, 21941-590,
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Protease-activated receptors (PAR) comprise a family of trans-
membrane G-coupled receptors (PAR-1, PAR-2, PAR-3 and PAR-4)
that are uniquely activated by proteolytic cleavage of their extracel-
lular portion. This cleavage “unmasks” a new N-terminus, which
serves as a “tethered ligand” that binds to the second extracellular
domain of the protein, resulting in a variety of cellular responses [1].
PAR-1, the prototypic receptor of the family, is activated by thrombin,
as well as other proteases, being associated with several physiological
and pathological processes [2].
Physiologically, PAR-1 is expressed by different tissues including
vascular cells, neurons, ﬁbroblasts, epithelial cells and others [2]. On
the other hand, PAR-1 has been recognized as an oncogene,
promoting transformation in NIH 3T3 cells [3]. PAR-1 has been
shown to be overexpressed in various human cancers types including
breast [4], melanoma [5,6], colon [7], prostate [8], ovarian [9],esophagus [10] and others. Moreover, studies employing cultured
cells have demonstrated strong correlation between PAR-1 expres-
sion and aggressive behavior [4,11]. Thus, PAR-1 has been associated
with several pro-tumoral responses in solid tumors including primary
growth, invasion, metastasis and angiogenesis [4,8,11–14].
Previous studies employing human leukemic cell lines have
demonstrated expression of PAR-1. Activation of PAR-1 elicits cell
signaling responses which have been associated with increased
production of interleukin 2 in Jurkat T cells [15]. In addition, PAR-1
is found in HL-60 cells [16] and its activation stimulates proliferation
and decreases idarubicin-induced cell death in vitro [17]. Based on
these data authors suggested that PAR-1 could play a role in the
leukemic process. However the status of PAR-1 expression in human
leukemic patients has not been fully evaluated.
The aim of this study was to evaluate the expression pattern of
PAR-1 receptor in patients with the four main types of leukemia –
chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia
(ALL), acute myeloid leukemia (AML) and chronic myeloid leukemia
(CML). Our data demonstrate for the ﬁrst time that PAR-1 is
signiﬁcantly elevated in more aggressive leukemias including blast
phase of CML, AML subtypes M4/M5 and ALL subtype B, in contrast to
chronic phase in CML and CLL subtype B. Therefore, this protein might
Table 1
Characteristics of the patients studied.
Sample Age Gender Diagnosis Circulating
blasts in
peripheral
blood (%)
WBC count
(×109/L)
Flow
cytometric
analysis of
PAR-1 (MFI)
1 64 F B-CLL 0 84.4 0.98
2 73 F B-CLL 0 34.4 1.56
3 77 F B-CLL 0 126.0 2.04
4 60 F B-CLL 0 32.6 2.09
5 68 M B-CLL 0 201.0 2.31
6 66 F B-CLL 0 58.2 2.50
7 66 M B-CLL 0 66.7 2.85
8 6 M B-ALL 68 26.6 2.03
9 32 M B-ALL 71 44.5 2.10
10 37 F B-ALL 96 4.2 2.12
11 15 M B-ALL 82 336.0 2.53
12 7 F B-ALL 52 2.0 2.78
13 17 F B-ALL 51 ND 5.6
14 9 M B-ALL 66 3.2 5.68
15 43 F B-ALL 57 13.5 6.48
16 62 M B-ALL 47 10.7 9.83
17 18 M B-ALL 64 11.0 10.36
18 67 M B-ALL 94 11.8 11.77
19 27 M AML-M3 71 2.6 1.38
20 15 F AML-M3 97 9.1 1.69
21 21 M AML-M3 86 169.0 2.10
22 32 F AML-M3 9 1.6 2.43
23 41 F AML-M3 67 15.1 2.52
24 40 F AML-M3 46 0.7 2.59
25 32 M AML-M3 44 1.7 2.70
26 39 M AML-M3 81 48.3 6.84
27 23 M AML-M3 100 134.0 8.53
28 3 M AML-M3 90 63.0 9.70
29 16 M AML-M4/M5 28 42.0 2.56
30 58 F AML-M4/M5 65 95.4 3.92
31 18 M AML-M4/M5 57 100.0 4.70
32 41 F AML-M4/M5 61 21.5 5.23
33 24 F AML-M4/M5 94 28.3 5.62
34 32 M AML-M4/M5 50 28.3 6.05
35 54 F AML-M4/M5 60 29.0 8.15
36 21 F AML-M4/M5 22 2.8 8.67
37 7 M AML-M4/M5 5 20.2 8.75
38 82 F AML-M4/M5 9 50.0 8.79
39 66 F AML-M4/M5 22 2.3 8.85
40 46 M AML-M4/M5 53 200.7 10.26
41 69 F AML-M4/M5 13 76.6 17.06
42 43 F AML-M4/M5 74 42.2 20.99
43 39 M AML-M4/M5 37 91.0 25.71
44 22 F AML-M4/M5 53 4.8 26.52
45 36 F CML-CP 1 64.7 0.68
46 51 F CML-CP 3 127.0 1.00
47 37 M CML-CP 0 102.0 1.01
48 26 F CML-CP 0 186.0 1.01
49 53 M CML-CP 5 175.0 1.04
50 19 M CML-CP 16 420.0 1.05
51 26 F CML-CP 7 242.0 1.06
52 35 M CML-CP 2 33.9 1.10
53 37 F CML-CP 5 434.7 1.11
54 47 M CML-CP 0 150.0 1.35
55 11 M CML-BP 100 240.0 0.96
56 25 F CML-BP 35 32.1 4.16
57 34 M CML-BP 40 16.7 5.48
58 34 F CML-BP 20 128.0 6.21
59 29 F CML-BP 75.5 4.0 10.84
60 35 F CML-BP 38 15.7 22.04
61 46 M CML-BP 60 11.7 34.65
F= female; M=male; MI=Mean ﬂuorescence intensity; B-CLL=B-chronic
lymphocytic leukemia; B-ALL = B-acute lymphoblastic leukemia; AML-M3=acute
myeloid leukemia subtype M3; AML-M4/M5=acute myeloid leukemia subtypes M4
and M5; CML-CP=chronic myeloid leukemia in chronic phase; CML-BP = chronic
myeloid leukemia in blast phase; ND=non-determined.
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offer additional strategies for the development of new therapies.
Materials and methods
Patient samples
To assess the protein expression pattern of PAR-1, we prospec-
tively analyzed 61 peripheral blood samples (Table 1) of 7 patients
with B-chronic lymphocytic leukemia (B-CLL), 11 with B-acute
lymphoblastic leukemia (B-ALL), 10 with acute myeloid leukemia
(AML) subtype M3, 16 with AML subtypes M4 and M5, 6 with chronic
myeloid leukemia (CML) in chronic phase and 7 with CML in blast
phase. Patients were from Instituto Estadual de Hematologia Arthur
de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro, Brazil. The median
age was 35 years (range 3–82 years). Diagnosis followed the criteria
proposed by the FAB classiﬁcation [18]. Patients with B-ALL were
stratiﬁed into high and low risk according to the following
parameters: presence or absence of tumor mass and visceromegalies,
leukocyte number, measurement of DHL and response to treatment.
For analysis of mRNA, 32 samples from patients with CML (23 in
chronic phase and 9 in blast crisis) from Hospital das Clínicas da
Faculdade de Medicina de Ribeirão Preto,Universidade de São Paulo,
were included in this study. Peripheral blood samples from healthy
donors were used as control for analysis of PAR-1 expression in
lymphocytes, monocytes and granulocytes. This study was approved
by the Ethics Committee at HEMORIO and USP and an informed
consent was obtained from each patient.
Flow cytometry analysis
Expression of PAR-1 was evaluated by ﬂow cytometry employing
whole peripheral blood collected in EDTA tubes from healthy donors
and leukemic patients. Cell concentration was adjusted to 1×106
cells/mL and incubated with 1 mL of phosphate buffered saline (PBS)
containing 2% fetal calf serum for 15 min at room temperature in
order to prevent nonspeciﬁc antigen-antibody complexes. Samples
were then centrifuged at 2000 rpm for 5 min and the supernatant
discarded. Cells were further incubated for 30 min, at 4 °C in dark,
with phycoerythrin-labeled murine monoclonal antibodies against
human PAR-1 (sc-13503, Santa Cruz Biotechnology Inc, USA) or
isotype controls (normal mouse IgG1, Santa Cruz Biotechnology Inc.,
USA). After washing to remove unbound antibody, red cells were
removed by incubation for 10 min with 2 mL of lysis solution
(FACSLysing, ca349202, BD Biosciences, San Jose, CA) and centrifuged
for 5 min at 2000 rpm. Cells were washed again and analyzed using a
FACScalibur (Becton-Dickinson, USA). The mean ﬂuorescence inten-
sity (MFI) of 10,000 events was determined for each sample and data
further analyzed using the CellQuest software. Patients evaluated in
this study were classiﬁed according to their immunophenotypic
proﬁle, based on the presence or absence of speciﬁc cell surface
markers for each type of leukemia. Based on the expression of these
cell markers, we identiﬁed the population of mature neoplastic cells
from chronic leukemias or the population of blast cells from acute
leukemias. Samples were further gated for analysis of PAR-1
expression. Cell surface markers for mature cells along with analysis
of cell size and citoplasmatic granularity have been used to generate
gates to evaluate lymphocytes, monocytes and granulocytes from
peripheral blood collected from healthy donors.
RNA isolation and reverse transcriptase real-time PCR
Blood samples were collected in EDTA from healthy donors and from
patients diagnosed with CML-CP or CML-BP. Peripheral blood mononu-
clear cells (PBMC) were further isolated by Ficoll-Histopaque® density
gradient centrifugation (Sigma-Aldrich Co., USA). Isolated cells werewashed twice in PBS and total RNAwas extracted using TRIZOL® reagent
(Invitrogen, USA) following the manufacturer's instructions. After cDNA
synthesis using Superscript III reverse transcriptase (Invitrogen), mRNA
levels were determined by quantitative polymerase chain reaction
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Biosystems) using Power SYBR® Green PCR Master Mix (Applied
Biosystems). The reaction conditionswere: 50 °C for 2 min and 95 °C for
10 min followed by 40 cycles of 95 °C for 15 s (denaturation) and 60 °C
for 1 min and the melt curve protocol began immediately after
ampliﬁcation. Lack of variation in PCR products and the absence of
primer dimmerswere ascertained from themelt curve proﬁle of the PCR
products. β-actin was used as endogenous control. Primers used were:
PAR-1 (F: 5′-CAGGCACTACAAATACTGTGG-3′, R: 5′-TGTAGACTTGATT-
GACGGGTT-3′) and β-actin (F: 5′-CCAGATCATGTTTGAGACCTT-3′,
R: 5′-CGGAGTCATCACGATGCCAG-3′).Statistical analysis
Results were analyzed by unpaired t test using Prism 4™ of
Graphpad software. Results were expressed as mean±standard
deviation. Data were considered statistically signiﬁcant for pb0.05.Results
Expression of PAR-1 in B-CLL and B-ALL
Expression of PAR-1 has been commonly associated with a more
aggressive behavior in solid tumors. In this context we ﬁrst analyzed
PAR-1 expression in lymphocytes from patients diagnosedwith B-CLL,
which is considered a non-aggressive hematological disease [19], as
compared to B-ALL, which shows a more aggressive clinical behavior
[20]. As control, we analyzed the expression pattern of PAR-1 in
lymphocytes from healthy donors. Flow cytometry analyses show that
lymphocytes from B-CLL patients express this receptor at similar
levels to healthy individuals (MFI=2.0±0.2 in B-CLL vs MFI=1.6
±0.1 in healthy donors). On the other hand, it was observed a
signiﬁcant increase in PAR-1 expression in B-ALL lymphocytes
(MFI=5.6±1.1) as compared to B-CLL and healthy donors (Fig. 1).
However, this observation is clearly heterogeneous, since some
patients displayed a high expression pattern of PAR-1 (MFIN5.0)
while others exhibited expression levels that are similar to those
observed in lymphocytes from B-CLL and healthy individuals (see
Table 1).Fig. 1. Flow cytometric analysis of PAR-1 in B-CLL and B-ALL. Peripheral blood samples
from healthy donors (n=10), B-CLL (n=7) and B-ALL patients (n=11) were labeled
with anti-PAR-1 antibodies and analyzed by ﬂow cytometry as described in Materials
and Methods. Statistical signiﬁcance was assessed by unpaired t test.PAR-1 expression in CML
CML is a myeloproliferative disease which presents an indolent,
non-aggressive chronic phase (CML-CP) and an aggressive, blast
(acute) phase (CML-BP) [21]. Given this, we performed a comparative
analysis of PAR-1 expression in mature neoplastic granulocytic cells
(CML-CP) and blast cells (CML-BP) from CML patients (Fig. 2). As
control, we analyzed PAR-1 expression in granulocytes from healthy
donors. Interestingly, it was observed a statistically signiﬁcant
decrease in the expression of PAR-1 in granulocytes from CML-CP
patients (MFI=1.0±0.05) as compared to healthy donors (MFI=2.3
±0.3). In contrast, a signiﬁcant increase in PAR-1 expression was
detected in the granulocytes of CML-BP patients (MFI=12.0±4.6).
As seen in B-ALL patients, PAR-1 expression levels were highly
heterogeneous in CML-BP, with MFI values ranging from 0.96 to 34.65
(see Table 1).
We further analyzed PAR-1 expression by quantitative real-time
PCR, by employing a collection of mRNA from 32 patients diagnosed
with CML. Differently from protein expression data, Fig. 3 shows that
PAR-1mRNA levels in CML-CP cells do not differ from that observed in
healthy donors. Comparison between CML-BP and CML-CP showed a
signiﬁcant, although heterogeneous, increase in PAR-1 mRNA levels
thus conﬁrming results obtained by ﬂow cytometry.Expression of PAR-1 receptor in AML
In order to evaluate PAR-1 expression in AML, we further analyzed
samples from patients diagnosed with AML subtype M3. Analysis of
PAR-1 expression in promyeloblasts from AML-M3 patients was
compared to receptor expression on granulocytes from healthy
individuals. Fig. 4A shows that PAR-1 expression in AML-M3 patients
(MFI=4.0±1.0) showed no statistical difference in relation to
healthy individuals (MIF=2.3±0.3). It is important to note, however,
that three patients showed high PAR-1 expression levels (Table 1).
Acute myelomonocytic leukemia comprises subtypes M4 and M5
in which AML-M4 is characterized by the presence of 20–80% of blast
cells in the bone marrow monocytic component while AML-M5
exhibits 80% or more of non-erythroid cells in bone marrow, i.e.,
monoblasts, promonocytes or monocytes [18]. Therefore, analysis of
PAR-1 expression was performed in patients with AML-M4/M5 as a
single group. Results were compared to PAR-1 expression levels inFig. 2. Flow cytometric analysis of PAR-1 in CML. Peripheral blood samples from healthy
donors (n=10), CML-CP (n=6) and CML-BP patients (n=7) were labeled with anti-
PAR-1 antibodies and analyzed by ﬂow cytometry as described in Materials and
Methods. Statistical signiﬁcance was assessed by unpaired t test.
Fig. 3. Analysis of PAR-1 expression in CML by q-PCR. PAR-1 gene expression was
evaluated in samples from healthy donors (n=8), CML-CP (n=23) and CML-BP
patients (n=9) by q-PCR as described in Materials and Methods. Results were
normalized to β-actin expression. Statistical signiﬁcance was assessed by unpaired t
test.
Fig. 4. Analysis of PAR-1 expression in AML. (A) Peripheral blood from healthy donors
(n=10) or samples from AML-M3 patients (n=10) were probed with anti-PAR-1
antibodies and analyzed by ﬂow cytometry as described in the Materials and Methods
section. (B) Peripheral blood from healthy donors (n=10) or samples from AML-M4/
M5 patients (n=16) were labeled with mAbs and analyzed by ﬂow cytometry for PAR-
1 expression. Statistical signiﬁcance was assessed by unpaired t test.
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that patients with AML-M4/M5 display an increased expression of
PAR-1 (MFI=10.7±1.9) as compared, respectively, to monocytes
(MFI=3.7±0.2) or granulocytes (MFI=2.3±0.3) from healthy
individuals. Most of the patients (10 out of 17) showed MFI values
above 8.0 (Table 1).
Discussion
Several lines of evidence suggest that the thrombin receptor, PAR-
1, plays a signiﬁcant role in tumor biology. In fact, PAR-1 mediates a
number of pro-tumoral responses being frequently overexpressed in
solid tumors [4–10]. In the present study, we attempted to evaluate
the expression pattern of PAR-1 in themain types of human leukemia.
Our results demonstrate for the ﬁrst time that PAR-1 is signiﬁcantly
elevated in more aggressive leukemias, including blast phase of CML,
AML subtypes M4/M5 and ALL subtype B, in contrast with chronic
phase in CML and CLL subtype B. These observations are in good
agreement with data reported by Depasquale and Thompson [6]
which demonstrated that PAR-1 expression is a negative prognostic
factor in melanomas and strongly correlates with tumor stage.
Patients with B-CLL, in most cases, have an indolent clinical course
which is asymptomatic and requires no treatment [19]. On the other
hand, B-ALL is believed to derive from blockade in maturation of bone
marrow lymphoid progenitors leading to bone marrow inﬁltration,
occurrence of various cytopenias in peripheral blood and appearance
of blast cells with high proliferative ability. Therefore, patients with
B-ALL showamore aggressive clinical behavior thanpatientswith B-CLL
[20]. In this study we observed that patients with B-CLL showed similar
PAR-1 expression levels in comparison to lymphocytes from healthy
individuals. On the other hand, patients with B-ALL exhibited, on
average, a signiﬁcant increase in the expression of this receptor when
compared to normal lymphocytes. Interestingly, patients classiﬁed as at
high risk showed the highest PAR-1 levels among B-ALL patients.
CML is a myeloproliferative disease which is characterized by the
presence of the fusion gene BCR-ABL, an oncoprotein generated by
reciprocal translocation between chromosomes 9 and 22, t(9;22) [21].
In this study, ﬂow cytometric analyses demonstrated that CML patients
in the chronic phase (CML-CP) exhibited a signiﬁcant decrease in PAR-1
when compared to granulocytes from healthy individuals. Since PAR-1
has been implicated in inﬂammatory responses as well as in innate and
adaptive immunity [22], it is possible that down-regulation of thisreceptor may contribute for reduced function of these cells and
increased susceptibility to recurrent infections in CML. Progression of
CML-CP to CML-BP is not fully understood. In fact it is believed that
BCR-ABL in cooperation with other factors may account for accelerated
leukemogenesis and drug resistance in the acute phase [21]. In this
study, we identiﬁed an increased PAR-1 expression in blasts from
CML-BP patients. However, it is clear that a more extensive analysis
is needed to determine the biological signiﬁcance of these results.
Acutemyelomonocytic leukemia,which comprises subtypesM4and
M5, are highly aggressive and have a median survival time of only
12 months [23]. Samples fromAML-M4/M5patients thatwere analyzed
in this study exhibited high levels of PAR-1 receptor when compared to
monocytes and granulocytes from healthy donors. In contrast, patients
with AML-M3 showed PAR-1 expression levels that were similar to
those found in granulocytes from healthy donors. However, 3 out of 10
patients exhibited high levels of this receptor. Interestingly, these
patients were non-responsive to treatment with trans-retinoic acid
(ATRA), a potent inducer of cell differentiation process [24], and further
died as consequence of hemorrhagic disturbances. In fact, patients with
AML-M3 are at increased thrombotic risk and hemorrhagic complica-
tions followingdisseminated intravascular coagulation (DIC) [25]. These
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the clotting initiator protein, tissue factor (TF), in blast cells [26,27].
Treatment with ATRA down-regulates TF expression and reduces
activation of blood coagulation in AML-M3 patients [28,29]. More
recently, Barbarroja and co-workers [30] suggested that TF is involved in
the activation of multiple signaling pathways in leukemic cells. At this
point, patients that are non-responsive to ATRA may exhibit an
increased TF-mediated thrombin generation and augmented activation
of PAR-1 in leukemic cells whichmay contribute to disease progression.
In this regard, it is proposed that TF inhibitors may reduce thrombin
generation and exert antitumor effects, at least in part, by indirectly
decreasing PAR-1 signaling [31].
In summary, our study demonstrates for the ﬁrst time that PAR-1
expression is signiﬁcantly elevated in more aggressive leukemias
including blast phase of CML, AML subtypes M4/M5 and ALL subtype
B, in contrast to chronic phase in CML and CLL subtype B. Therefore,
this protein might play an important biological role in aggressive
hematologicmalignancies andmight offer additional strategies for the
development of new therapies.
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